Journal of Clinical Oncology
Articles in this Issue
Feasibility of surgical orchiectomy in prostate cancer patients on long term luteinizing hormone-releasing hormone (LHRH) agonist therapy.
265 Background: Androgen deprivation, achieved through surgical or medical castration, is central to metastatic prostate cancer (PCa) treatment. Life-long...
Trends and demographic disparities in the preferred place of death for bladder cancer patients in the United States (2000–2020): An analysis from the CDC database.
747 Background: Understanding trends in end-of-life care for bladder cancer patients, particularly their preferred place of death (PPOD), is essential for...
Defining subgroups of patients with intermediate risk prostate cancer for whom active surveillance is safe.
393 Background: A number of guideline groups recommend active surveillance (AS) for patients with low risk prostate cancer as well as selected patients wi...
Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer.
33 Background: PSMA-PET/CT is increasingly being used to monitor chemotherapy in prostate cancer and shows promise for predicting outcomes and improving r...
PSA response to Lu177-PSMA-617 in patients experiencing xerostomia and ocular dryness in metastatic castration resistant prostate cancer.
127 Background: Lu177-PSMA-617 (PSMA Lu177) therapy can cause dry mouth and/or eyes, as prostate specific membrane antigen (PSMA) is expressed in salivary...
Relationship of spatial transcriptomic analyses with distance-associated transcriptomic spectrum and morphology-specific signatures of localized prostate cancer.
422 Background: Current clinical management and classification of prostate cancer is dependent upon specimen morphology assessment. Limited studies have f...
A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT).
TPS882 Background: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the standard of care for muscle-invasive bladder cancer (MIB...
Prognostic impact of germline deleterious variants and variants of uncertain significance in advanced prostate cancer: A call for functional elucidation.
211 Background: Prostate cancer remains the most prevalent solid tumor in men and the third leading cause of cancer-related mortality globally. Tumor aggr...
Patient satisfaction with geriatric and functional assessments and referral to frailty-related interventions among older adults presenting to the University of Colorado Urologic Oncology Multidisciplinary Clinic.
TPS273 Background: Geriatric assessments (GA) are valuable tools for determining the functional age of patients and represent the standard of care in eval...
Hypofractionated radiotherapy for prostate cancer (HYDRA): An individual patient data meta-analysis of randomized trials in the MARCAP consortium.
385 Background: Trials comparing moderately hypofractionated radiotherapy (MHFRT) against conventionally-fractionated radiotherapy (CFRT) for prostate can...
Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC).
833 Background: EV has high antitumor activity and improved survival in advanced urothelial cancer both as a single agent and in combination with pembroli...
Low versus low-intermediate risk metastatic renal cell carcinoma (mRCC): Contemporary data from the International mRCC Database Consortium (IMDC).
505 Background: The IMDC model has been effectively used to predict patients’ (pts) outcomes with mRCC, significantly guiding treatment decisions in the e...
Real-world outcomes of first-line dual immunotherapy versus combination VEGF immunotherapy in intermediate-poor risk metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Data Consortium (IMDC).
477 Background: Multiple phase 3 trials have established either dual immunotherapy with ipilimumab and nivolumab (IPI-NIVO) or immunotherapy with a VEGFR...
Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors.
791 Background: Radical nephroureterectomy (RNU) is the standard treatment for localized high-risk upper tract urothelial carcinoma (UTUC). However, the p...
Clinical outcomes disparities in prostate cancer in the Caribbean: Results from 504 patients from the Martinique cohort.
314 Background: Ethnic and geographic disparities in cancer care access is an issue. French West Indies has one of the world highest incidence of prostate...
Evaluating the contribution of circulating tumor DNA (ctDNA) towards magnetic resonance imaging (MRI) in clinical staging and response assessment of patients with muscle-invasive bladder cancer (MIBC).
798 Background: In patients (pts) with MIBC, optimizing clinical staging (cT-stage) and response assessment after neoadjuvant therapies has become critica...
Extensive necrosis as a prognostic indicator in metastatic RCC patients undergoing deferred cytoreductive nephrectomy after immunologic checkpoint inhibitor treatment.
468 Background: The role of cytoreductive nephrectomy (CN) in patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor...
Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.
544 Background: Non-clear cell renal cell carcinoma (nccRCC) accounts for approximately 25% of all renal cell carcinoma (RCC) and lacks standards of care....
Understanding health inequalities based on socio-economic factors and geographical location in renal cell carcinoma: A large-scale national cohort study in England.
464 Background: Kidney cancer is 7 th most common cancer in England with renal cell carcinoma (RCC) accounting for about 80% of al...
<i>NECTIN4</i> RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): Exploratory analyses from JAVELIN Bladder 100.
827 Background: Nectin-4 is widely expressed in UC tumors, although protein expression levels vary between patients. Prior analyses have suggested that lo...
Prostate cancer risk groups by PSMA-PET PROMISE (PPP): Results from an international multi-center registry study.
266 Background: We previously established prognostic nomograms of PSMA-PET standardized by Prostate Cancer Molecular Imaging Standardized Evaluation (PROM...
Impact of specimen type on digital histopathology-based multimodal artificial intelligence (MMAI) biomarker risk score: Whole slide image vs tissue microarray.
400 Background: The ArteraAI Prostate Test (v1.2), a digital pathology-based multimodal artificial intelligence (MMAI) biomarker, was developed and valida...
Efficacy and safety of fexagratinib (Fexa) in Chinese patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) harboring FGF receptor (FGFR) genetic alterations.
790 Background: Fexagratinib (former AZD4547), a selective and potent oral inhibitor of FGFR1-3, has shown promising efficacy and safety in phase I trials...
PRO-XL: A phase II study of zanzalintinib (XL092) in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on lutetium-177 (177Lu)-PSMA-617.
TPS285 Background: 177Lu-PSMA-617 has been approved for patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who have been treated with...
Germline DNA repair gene variants in patients under active surveillance for low-grade bladder cancer: Implications for risk stratification.
849 Background: The growing interest in de-intensifying therapeutic strategies for low-grade bladder cancer (BC), including active surveillance (AS), high...